Envestnet Asset Management Inc. Invests $385,000 in Evotec AG $EVO

Envestnet Asset Management Inc. bought a new position in shares of Evotec AG (NASDAQ:EVO) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 91,664 shares of the company’s stock, valued at approximately $385,000.

Other institutional investors also recently modified their holdings of the company. DCF Advisers LLC lifted its position in shares of Evotec by 227.0% during the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company’s stock worth $2,510,000 after purchasing an additional 521,708 shares during the last quarter. WCM Investment Management LLC bought a new position in Evotec during the second quarter worth $1,239,000. ABC Arbitrage SA bought a new stake in Evotec in the 1st quarter valued at $260,000. UMB Bank n.a. acquired a new stake in Evotec in the 2nd quarter worth $56,000. Finally, Bank of America Corp DE increased its holdings in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Institutional investors own 5.81% of the company’s stock.

Analysts Set New Price Targets

EVO has been the topic of a number of recent research reports. HC Wainwright decreased their price target on shares of Evotec from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Royal Bank Of Canada reissued an “outperform” rating on shares of Evotec in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a research report on Monday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.00.

Evotec Stock Up 0.9%

Shares of EVO stock opened at $3.26 on Thursday. Evotec AG has a 12-month low of $2.84 and a 12-month high of $5.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.58 and a quick ratio of 1.49. The firm has a 50-day moving average price of $3.63 and a 200 day moving average price of $3.83.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.